New details from the Phase III OLYMPUS and ROCKIES trials show that roxadustat significantly increased hemoglobin (Hb) levels in certain people with anemia from chronic kidney disease (CKD).
AstraZeneca (LSE: AZN) presented the findings at the American Society of Nephrology (ASN) Kidney Week. Top-line results, which confirmed both trials met their primary endpoints, were revealed towards the end of 2018.
The drug is a novel first-in-class treatment for the condition, which the London-listed firm is developing in collaboration with American company FibroGen (Nasdaq: FGEN).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze